Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study

Multiple Sclerosis

Volumn 13, Issue 3, 2007, Pages 357-368

  Goodman, Andrew D ^a   Cohen, J A ^b   Cross, A ^c   Vollmer, T ^d,f   Rizzo, M ^d,g   Cohen, R ^e   Marinucci, L ^e   Blight, A R ^e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ACORDA THERAPEUTICS INC   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g GENZYME CORPORATION   (United States)

Author keywords

4 aminopyridine; Clinical trial; Fampridine SR; Multiple sclerosis; Safety

Indexed keywords

4 AMINOPYRIDINE; BACLOFEN; CLONAZEPAM; PLACEBO; TIZANIDINE;

ACCIDENTAL INJURY; ADULT; ARTICLE; ASTHENIA; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EEG ABNORMALITY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; NAUSEA; PARESTHESIA; POST HOC ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREMOR; WALKING SPEED;

4-AMINOPYRIDINE; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MUSCLE STRENGTH; PLACEBOS; SAFETY; TREATMENT OUTCOME; WALKING;

EID: 34248221564     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506069538     Document Type: Article

References (29)

1. Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004; 85: 29-34.
2. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985; 328: 358-61.
3. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22: 47-52.
4. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991; 8: 103-19.
5. Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 1993; 10: 19-24.
6. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77.
7. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344-48.
8. Bever CT Jr, Young D, Anderson PA, Panitch HS, Dhib-Jalbut S, Khan OA et al. The effects of 4-ammopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054-59.
9. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997; 48: 817-21.
10. van Diemen HAM, Polman CH, van Dongen TMMM, van Loenen AC, Nauta JJP, Taphoorn MJB et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123-30.
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
12. Sanders DB, Kim YI, Howard JF Jr, Goetsch CA. Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine. J Neurol Neurosurg Psychiatry 1980; 43: 978-85.
13. Jones RE, Heron JR, Foster DR, Snelgar RS, Mason. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-62.
14. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186-92.
15. Lundh H, Nilsson O, Rosén I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979; 42: 171-75.
16. Ball AP, Hopkinson RB, Farrell ID, Hutchison JG, Paul R, Watson RD et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979; 48: 473-91.
17. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265-71.
18. Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980; 16: 487-97.
19. van Diemen HAM, Polman CH, Koetsier JC, van Loenen AC, Nauta JJP, Bertelsmann. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993; 16: 195-204.
20. Schwid SR, Goodman AD, Mattson DR, Minai C, Donohoe KM, Petrie MD et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419-24.
21. Balcer LJ. Clinical outcome measures for research in multiple sclerosis. J Neuroophthalmol 2001; 21: 296-301.
22. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davies FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-23.
24. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK et al. The rapid assessment of fatigue severity in cancer patients. Cancer 1999; 85: 1186-96.
25. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999; 5: 251-59.
26. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
27. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual. Retrieved 30 March 2005, from http://www.nationalmssociety.org/%SCMUCS_MSFC.asp
28. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak K, Petrie MD et al. Quantitative assessment of motor fatigue and strength in multiple sclerosis. Neurology 1999; 53: 743-50.
29. Ghezzi A, Montanini R, Basso PF, Zaffaroni M, Massimo E, Cazzullo CL. Epilepsy in multiple sclerosis. Eur Neurol 1990; 30: 218-23.